AZD7762
目录号:S1532 Purity: 99.99%
AZD7762是一种有效的,选择性Chk1抑制剂,无细胞试验中IC50为5 nM,作用于Chk2也同样有效,对CAM, Yes, Fyn, Lyn, Hck和Lck作用效果稍弱。Phase 1。
CAS: 860352-01-8
客户使用Selleck的AZD7762发表文献130篇
- Cell, 2022 185(16):2988-3007.e20
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Cancer Cell, 2019 35(5):752-766
- Cancer Cell, 2019 35(6):851-867
- Nat Cell Biol, 2019 21(6):778-790
- J Thorac Oncol, 2019 14(6):1032-1045
- Cancer Discov, 2012 2(6):524-39
- Nat Biotechnol, 2011 29(6):542-6
- Mol Cell, 2024 S1097-2765(24)00285-5
- Pharmacol Res, 2024 201:107091
- Cell Death Dis, 2024 15(4):274
- Cell Rep, 2024 43(5):114205
- Lung Cancer, 2024 197:107986
- Cell Genom, 2024 4(2):100487
- Mol Cell, 2023 83(5):803-818.e8
- EMBO Mol Med, 2023 e16431.
- Cell Death Discov, 2023 9(1):313
- Aging (Albany NY), 2023 15(2):492-512
- J Biol Chem, 2023 S0021-9258(23)00089-3
- Sci Adv, 2023 9(42):eadg0898
- SSRN, 2023 35 Pages
- Nat Commun, 2022 13(1):4689
- Nat Commun, 2022 13(1):4261
- Mol Cell, 2022 82(18):3350-3365.e7
- J Exp Clin Cancer Res, 2022 41(1):141
- Cell Rep, 2022 38(3):110261
- Breast Cancer Res, 2022 24(1):41
- Int J Mol Sci, 2022 23(13)7051
- Cancers (Basel), 2022 14(6)1575
- Front Oncol, 2022 12:852859
- Sci Rep, 2022 12(1):5827
- Cancer Genomics Proteomics, 2022 19(3):328-338
- APL Bioeng, 2022 6(4):046106
- Theranostics, 2021 11(4):1795-1813
- Leukemia, 2021 10.1038/s41375-021-01347-6
- Haematologica, 2021 10.3324/haematol.2021.278743
- Cell Rep, 2021 34(11):108870
- Cell Rep, 2021 37(9):110060
- JCI Insight, 2021 e154402
- Radiother Oncol, 2021 157:175-181
- Cancers (Basel), 2021 13(15)3717
- Sci Rep, 2021 11(1):19138
- Sci Adv, 2021 7(25)eabd9208
- Mol Biomed, 2021 2(1):19
- Nat Commun, 2020 29;11(1):2086
- Mol Cell, 2020 22 pii: S1097-2765(20)30231-8
- J Clin Invest, 2020 139080
- Nucleic Acids Res, 2020 48(17):9710-9723
- Biomaterials, 2020 248:120032
- Haematologica, 2020 105(3):784-795
- Cell Death Dis, 2020 28;11(4):298
- Cell Rep, 2020 31(12):107800
- Cell Rep, 2020 12;31(6):107632
- Cell Rep, 2020 30(7):2416-2429
- Oncogene, 2020 10.1038/s41388-020-1300-x
- Mol Oncol, 2020 10.1002/1878-0261.12882
- Int J Mol Sci, 2020 21(18)E6692
- Cancers (Basel), 2020 12(7):1726
- Cancers (Basel), 2020 12(9)E2498
- Life Sci Alliance, 2020 3(8):e202000671
- Radiat Environ Biophys, 2020
- Clin Cancer Res, 2019 25(7):2290-2304
- Br J Pharmacol, 2019 10.1111/bph.14916
- Cancer Cell Int, 2019 19:195
- Mol Cancer Ther, 2019 18(4):762-770
- Mol Cancer Ther, 2019 10.1158/1535-7163.MCT-19-0290
- Mol Cancer Ther, 2019 18(8):1439-1450
- Mol Cancer Ther, 2019 10.1158/1535-7163.MCT-19-0474
- Oncotarget, 2019 10(62):6691-6712
- Mol Cancer Res, 2019 17(10):1985-1998
- Cancers (Basel), 2019 11(8)
- Cell Cycle, 2019 18(8):834-847
- Nucleic Acids Res, 2018 46(10):5029-5049
- Clin Cancer Res, 2018 24(7):1629-1643
- Cancer Lett, 2018 431:142-149
- Cell Rep, 2018 24(13):3393-3403.e5
- Diabetes, 2018 67(11):2319-2328
- Oncotarget, 2018 9(71):33589-33600
- Chem Res Toxicol, 2018 31(7):612-618
- Cancer Med, 2018 7(8):3955-3964
- Cancer Biol Ther, 2018 19(7):609-621
- Nat Commun, 2017 8(1):1392
- J Exp Clin Cancer Res, 2017 36(1):1
- Proc Natl Acad Sci U S A, 2017 114(24):E4782-E4791
- Haematologica, 2017 102(5):826-834
- Cancer Lett, 2017 392:71-82
- Cell Syst, 2017
- Cell Rep, 2017 18(8):1970-1981
- J Virol, 2017 91(24)e01712-17
- Oncotarget, 2017 8(7):10966-10979
- Sci Rep, 2017 7(1):1535
- Eur J Pharm Sci, 2017 109:223-232
- Tumour Biol, 2017 39(3):1010428317694307
- Cancer Res, 2016 76(11):3319-31
- Oncogene, 2016 35(36):4689-97
- PLoS Pathog, 2016 12(2):e1005424
- Oncotarget, 2016 7(23):34688-702
- Oncotarget, 2016 7(14):18159-70
- Mol Cancer Res, 2016 14(5):437-47
- J Biol Chem, 2016 291(17):9330-42
- Sci Rep, 2016 6:22230
- Anticancer Res, 2016 36(6):2649-57
- J Pathol, 2015 10.1002/path.4528
- Biochem Pharmacol, 2015 93(2):210-20
- Oncotarget, 2015
- Oncotarget, 2015 6(35):37229-40
- Oncotarget, 2015 6(25):21074-84
- J Biol Chem, 2015 290(3):1874-84
- Sci Rep, 2015 5:9357
- BMC Cancer, 2015 15:462
- PLoS One, 2015 10(6):e0129090
- Mol Biol Cell, 2015 26(12):2217-26
- Genom Data, 2015 6:118-9
- Cell Death Dis, 2014 5:e1223
- Cell Death Dis, 2014 5:e1253
- Cell Rep, 2014 10.1016/j.celrep.2014.10.024
- Cell Rep, 2014 9(4):1375-86
- Sci Signal, 2014 7(326):ra47
- Oncotarget, 2014 5(21):10546-57
- Int J Oncol, 2014 45(3):1159-66
- Int J Gynecol Cancer, 2014 24(5):838-43
- PLoS One, 2014 9(10):e111146
- Br J Cancer, 2013 110(2):510-9
- J Virol, 2013 87(16):9173-88
- J Cell Mol Med, 2013 18(1):143-55
- PLoS One, 2013 8(2):e55493
- Cancer Biol Ther, 2012 13(6):379-88
- Cancer Biol Ther, 2011 12(3):215-28
- PLoS One, 2010 5(12):e14335
化学信息&溶解度
分子量 | 362.42 |
分子式 | C17H19FN4O2S |
CAS号 | 860352-01-8 |
Smiles | C1CC(CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 73 mg/mL ( 201.42 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 3 mg/mL Water : Insoluble DMSO : 73 mg/mL ( 201.42 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 72 mg/mL ( 198.66 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 72 mg/mL ( 198.66 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。